MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ejim.2021.08.020

Медицинская библиотека · European journal of internal medicine · 2021

Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care.

Taramasso Lucia, Magnasco Laura, Portunato Federica, Briano Federica, Vena Antonio, Giacobbe Daniele R, Dentone Chiara, Robba Chiara, Ball Lorenzo, Loconte Maurizio, Patroniti Nicolò, Frisoni Paolo, D'Angelo Raffaele, Dettori Silvia, Mikulska Malgorzata, Pelosi Paolo, Bassetti Matteo

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

The hypothesis of this study is that tocilizumab should affect common signs of infection due to its immunosuppressive properties. Primary aim of the study was to investigate whether the administration of tocilizumab to critically ill patients with COVID-19, led to a different clinical presentation of infectious complications compared to patients who did not receive tocilizumab. Secondary aim was investigating differences in laboratory parameters between groups.

METHODS

Single-centre retrospective study, enrolling COVID-19 patients who developed a microbiologically confirmed infectious complication [ventilator associated pneumonia or bloodstream infection] after intensive care unit [ICU] admission and either treated with tocilizumab or not [controls].

RESULTS

A total of 58 patients were included, 25 treated with tocilizumab and 33 controls. Median time from tocilizumab administration to infection onset was 10 days [range 2-26]. Patients were 78% male, with median age 65 years [range 45-79]. At first clinical presentation of the infectious event, the frequency of hypotension [11/25, 44% vs. 11/33, 33%], fever [8/25, 32% vs. 10/33, 30%] or hypothermia [0/25,0%, vs. 2/33, 6%], and oxygen desaturation [6/25, 28% vs 4/33, 12%], as well as the frequency of SOFA score increase of ≥ 2 points [4/25, 16%,vs. 4/33, 12%] was similar in tocilizumab treated patients and controls [p>0.1 for all comparisons]. Among laboratory parameters, C-Reactive Protein elevation was reduced in tocilizumab treated patients compared to controls [8/25, 32% vs. 22/33, 67%, p=0.009].

CONCLUSION

The clinical features of infectious complications in critically ill patients with COVID-19 admitted to ICU were not affected by tocilizumab.

Для цитирования: Taramasso Lucia, Magnasco Laura, Portunato Federica, Briano Federica, Vena Antonio, Giacobbe Daniele R, Dentone Chiara, Robba Chiara, Ball Lorenzo, Loconte Maurizio, Patroniti Nicolò, Frisoni Paolo, D'Angelo Raffaele, Dettori Silvia, Mikulska Malgorzata, Pelosi Paolo, Bassetti Matteo. Clinical presentation of secondary infectious complications in COVID-19 patients in intensive care unit treated with tocilizumab or standard of care.. European journal of internal medicine. 2021. DOI: 10.1016/j.ejim.2021.08.020.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.